In 1988 Van de Water and et al. introduced Nebivolol as a generation beta blocker mainly used to treat hypertension. It was approved by the FDA in 2007. Its strong preference, for β1 receptors along with its ability to dilating blood vessels sets it apart from beta blockers. Not does Nebivolol reduce side effects such as aggravating lung conditions and erectile dysfunction but it has also shown promise in cancer treatment particularly in uveal melanoma.
Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about NEBIMED 5 by Deus Medical, consult with your doctor or healthcare professional.
Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.
Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.
Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.
Home
